Skip to main content

Table 2 Clinical characteristics grouped by different SUV and EBV DNA level

From: Maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients

 

SUVmax-T n(%)

SUVmax-N n(%)

SUVmax-M n(%)

EBV DNA n(%)

Characteristic

  

P value

  

P value

  

P value

  

P value

Total

175

78

 

104

149

 

77

176

 

95

158

 

Gender

 Male

148(84.6%)

68(87.2%)

0.701

88(84.6%)

128(85.9%)

0.857

67(87.0%)

149(84.7%)

0.702

78(82.1%)

138(87.3%)

0.274

 Female

27(18.2%)

10(12.8%)

 

16(15.4%)

21(14.1%)

 

10(13.0%)

27(15.3%)

 

17(17.9%)

20(12.7%)

 

Age (years)

  ≤ 47

88(50.3%)

45(57.7%)

0.340

49(47.1%)

84(56.4%)

0.161

42(54.5%)

91(51.7%)

0.684

50(52.6%)

83(52.5%)

> 0.999

  > 47

87(49.7%)

33(42.3%)

 

55(52.9%)

65(43.6%)

 

35(45.5%)

85(48.3%)

 

45(47.4%)

75(47.5%)

 

T stage #

 T1

10(5.7%)

2(2.6%)

0.089

7(6.7%)

5(3.4%)

0.187

4(5.2%)

8(4.5%)

0.984

5(5.3%)

7(4.4%)

0.008

 T2

19(10.9%)

3(3.8%)

 

7(6.7%)

15(10.1%)

 

7(9.1%)

15(8.5%)

 

15(15.8%)

7(4.4%)

 

 T3

93(53.1%)

40(51.3%)

 

49(47.1%)

84(56.4%)

 

39(50.6%)

94(53.4%)

 

50(52.6%)

83(52.5%)

 

 T4

53(30.3%)

33(42.3%)

 

41(39.4%)

45(30.2%)

 

27(35.1%)

59(33.5%)

 

25(26.3%)

61(38.6%)

 

N stage #

 N0

4(2.3%)

0(0.0%)

0.525*

4(3.8%)

0(0.0%)

< 0.001*

2(2.6%)

2(1.1%)

0.332*

4(4.2%)

0(0.0%)

0.002*

 N1

21(12.0%)

7(9.0%)

 

18(17.3%)

10(6.7%)

 

8(10.4%)

20(11.4%)

 

13(13.7%)

15(9.5%)

 

 N2

66(37.7%)

28(35.9%)

 

42(40.4%)

52(34.9%)

 

34(44.2%)

60(34.1%)

 

42(44.2%)

52(32.9%)

 

 N3

84(48.0%)

43(55.1%)

 

40(38.5%)

87(58.4%)

 

33(42.9%)

94(53.4%)

 

36(37.9%)

91(57.6%)

 

Metastatic site sites

 Bone

87(49.7%)

29(37.2%)

0.056

58(55.8%)

58(38.9%)

0.005

31(40.3%)

85(48.3%)

< 0.001

47(49.5%)

69(43.7%)

0.001

 Lung

20(11.4%)

8(10.3%)

 

13(12.5%)

15(10.1%)

 

13(16.9%)

15(8.5%)

 

17(17.9%)

11(7.0%)

 

 Liver

8(4.6%)

6(7.7%)

 

5(4.8%)

9(6.0%)

 

5(6.5%)

9(5.1%)

 

5(5.3%)

9(5.7%)

 

 Distant nodes

18(10.3%)

4(5.1%)

 

11(10.6%)

11(7.4%)

 

15(19.5%)

7(4.0%)

 

11(11.6%)

11(7.0%)

 

 Multiple sites

42(24.0%)

31(39.7%)

 

17(16.3%)

56(37.6%)

 

13(16.9%)

60(34.1%)

 

15(15.8%)

58(36.7%)

 

LRRT use

 No

60(34.3%)

29(37.7%)

0.668

34(33.3%)

55(36.9%)

0.592

20(26.0%)

69(39.4%)

0.045

28(29.5%)

61(38.9%)

0.137

 Yes

115(65.7%)

48(62.3%)

 

69(67.0%)

94(63.1%)

 

57(74.0%)

106(60.6%)

 

67(70.5%)

96(61.1%)

 
  1. Abbreviations: LRRT locoregional radiotherapy
  2. According to the 8th edition of the UICC/AJCC staging system
  3. The P value was calculated with the Pearson χ2 test or Fisher’s exact test (*)
  4. Bold data referred to statistical significance (P < 0.05)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us